Document Detail


Erythropoiesis-stimulating agents and heart failure.
MedLine Citation:
PMID:  20973926     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Anemia is a common comorbidity in heart failure (HF) patients. Its occurrence and severity are associated with worse prognosis. Although the etiology of anemia is multifactorial, inappropriate erythropoietin (EPO) production and/or bone-marrow resistance to EPO appear crucial in majority of anemic HF patients. Consequently, treatment based on this pathophysiological background may prove to be most effective and beneficial. In a number of smaller clinical studies, administration of erythropoiesis-stimulating agents (ESAs) to anemic HF patients improved a number of surrogate endpoints, including left ventricular function, exercise capacity, renal function, and different quality of life parameters. However, two larger, phase II studies, did not fully confirm these promising results. Furthermore, many concerns have been raised on the safety of ESAs after the recent publication of studies correcting anemia in patients with chronic kidney disease (CKD). On the other hand, chronic HF population varies significantly from CKD patients, with different comorbidities, renal function, and etiology of anemia. Moreover, ESAs have been shown to possess robust nonhematopoietic effects in the heart, namely inhibition of apoptosis and stimulation of neovascularization. Therefore, large-scale trials with ESAs are required to examine the effect and safety of anemia treatment in HF patients.
Authors:
Erik Lipšic; Peter van der Meer; Dirk J van Veldhuisen
Related Documents :
17899346 - The resynchronization therapy in narrow qrs study (rethinq study): methods and protocol...
21092156 - Ip-10 detection in urine is associated with lung diseases.
16806536 - Using an individualised quality of life measure in older heart failure patients.
2212496 - Effects of sympathetic activation on heart rate variability in chagas' patients.
11798446 - Is routine fetal karyotyping necessary for patients undergoing amniocentesis for elevat...
10091146 - Bone pain in thalassaemia: assessment of dexa and mri findings.
Publication Detail:
Type:  Journal Article     Date:  2010-10-26
Journal Detail:
Title:  Cardiovascular therapeutics     Volume:  29     ISSN:  1755-5922     ISO Abbreviation:  Cardiovasc Ther     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101319630     Medline TA:  Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  e52-9     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Advancing the science of team science.
Next Document:  Allopurinol Attenuates Oxidative Stress and Cardiac Fibrosis in Angiotensin II-Induced Cardiac Diast...